keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimer imaging

keyword
https://www.readbyqxmd.com/read/28818990/clinical-use-and-utility-of-amyloid-imaging
#1
Henryk Barthel, Osama Sabri
Currently, three amyloid PET tracers are approved and commercially available for clinical use. They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer's disease (AD). Here, we review the current knowledge on the clinical use and utility of amyloid imaging. Appropriate use criteria for the clinical application of amyloid imaging are established, and most currently available data point to their validity. Visual amyloid image analysis is highly standardized. Disclosure of amyloid imaging results is desired by many cognitively impaired subjects, and seems to be safe once appropriate education is delivered to the disclosing clinicians...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818116/distinct-white-matter-microstructural-abnormalities-and-extracellular-water-increases-relate-to-cognitive-impairment-in-alzheimer-s-disease-with-and-without-cerebrovascular-disease
#2
Fang Ji, Ofer Pasternak, Siwei Liu, Yng Miin Loke, Boon Linn Choo, Saima Hilal, Xin Xu, Mohammad Kamran Ikram, Narayanaswamy Venketasubramanian, Christopher Li-Hsian Chen, Juan Zhou
BACKGROUND: Mixed vascular and neurodegenerative dementia, such as Alzheimer's disease (AD) with concomitant cerebrovascular disease, has emerged as the leading cause of age-related cognitive impairment. The brain white matter (WM) microstructural changes in neurodegeneration well-documented by diffusion tensor imaging (DTI) can originate from brain tissue or extracellular free water changes. The differential microstructural and free water changes in AD with and without cerebrovascular disease, especially in normal-appearing WM, remain largely unknown...
August 17, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28814675/retinal-amyloid-pathology-and-proof-of-concept-imaging-trial-in-alzheimer-s-disease
#3
Yosef Koronyo, David Biggs, Ernesto Barron, David S Boyer, Joel A Pearlman, William J Au, Shawn J Kile, Austin Blanco, Dieu-Trang Fuchs, Adeel Ashfaq, Sally Frautschy, Gregory M Cole, Carol A Miller, David R Hinton, Steven R Verdooner, Keith L Black, Maya Koronyo-Hamaoui
BACKGROUND: Noninvasive detection of Alzheimer's disease (AD) with high specificity and sensitivity can greatly facilitate identification of at-risk populations for earlier, more effective intervention. AD patients exhibit a myriad of retinal pathologies, including hallmark amyloid β-protein (Aβ) deposits. METHODS: Burden, distribution, cellular layer, and structure of retinal Aβ plaques were analyzed in flat mounts and cross sections of definite AD patients and controls (n = 37)...
August 17, 2017: JCI Insight
https://www.readbyqxmd.com/read/28811553/cascaded-multi-view-canonical-correlation-camcco-for-early-diagnosis-of-alzheimer-s-disease-via-fusion-of-clinical-imaging-and-omic-features
#4
Asha Singanamalli, Haibo Wang, Anant Madabhushi
The introduction of mild cognitive impairment (MCI) as a diagnostic category adds to the challenges of diagnosing Alzheimer's Disease (AD). No single marker has been proven to accurately categorize patients into their respective diagnostic groups. Thus, previous studies have attempted to develop fused predictors of AD and MCI. These studies have two main limitations. Most do not simultaneously consider all diagnostic categories and provide suboptimal fused representations using the same set of modalities for prediction of all classes...
August 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28810002/retinal-oximetry-discovers-novel-biomarkers-in-retinal-and-brain-diseases
#5
Einar Stefánsson, Olof Birna Olafsdottir, Anna Bryndis Einarsdottir, Thorunn Scheving Eliasdottir, Thor Eysteinsson, Wouter Vehmeijer, Evelien Vandewalle, Toke Bek, Sveinn Hakon Hardarson
Purpose: Biomarkers for several eye and brain diseases are reviewed, where retinal oximetry may help confirm diagnosis or measure severity of disease. These include diabetic retinopathy, central retinal vein occlusion (CRVO), retinitis pigmentosa, glaucoma, and Alzheimer's disease. Methods: Retinal oximetry is based on spectrophotometric fundus imaging and measures oxygen saturation in retinal arterioles and venules in a noninvasive, quick, safe manner. Retinal oximetry detects changes in oxygen metabolism, including those that result from ischemia or atrophy...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28809833/application-of-granger-causality-analysis-of-the-directed-functional-connection-in-alzheimer-s-disease-and-mild-cognitive-impairment
#6
Mei Wang, Zhengluan Liao, Dewang Mao, Qi Zhang, Yumei Li, Enyan Yu, Zhongxiang Ding
Impaired functional connectivity in the Default Mode Network (DMN) may be involved in the progression of Alzheimer's Disease (AD). The Posterior Cingulate Cortex (PCC) is a potential imaging marker for monitoring the progression of AD. Previous studies did not focus on the functional connectivity between the PCC and nodes in regions outside the DMN, but our study is an effort to explore these overlooked functional connections. For collecting data, we used functional Magnetic Resonance Imaging (fMRI) and Granger Causality Analysis (GCA)...
August 7, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28808912/molecular-imaging-and-updated-diagnostic-criteria-in-lewy-body-dementias
#7
REVIEW
Nicolaas I Bohnen, Martijn L T M Müller, Kirk A Frey
PURPOSE OF REVIEW: The aims of the study were to review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB). RECENT FINDINGS: There do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies...
August 14, 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28807158/effect-of-chinese-herbal-medicine-on-molecular-imaging-of-neurological-disorders
#8
Yao Yao, Ting Chen, Jing Huang, Hong Zhang, Mei Tian
Chinese herbal medicine has been used to treat a wide variety of neurological disorders including stroke, Alzheimer's disease, and Parkinson's disease. However, its mechanism behind the effectiveness remains unclear. Recently, molecular imaging technology has been applied for this purpose, since it can assess the cellular or molecular function in a living subject by using specific imaging probes and/or radioactive tracers, which enable efficient analysis and monitoring the therapeutic response repetitively...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28806518/in-vivo-biosynthesized-zinc-and-iron-oxide-nanoclusters-for-high-spatiotemporal-dual-modality-bioimaging-of-alzheimer-s-disease
#9
Lanmei Lai, Xuerui Jiang, Shanying Han, Chunqiu Zhao, Tianyu Du, Fawad Ur Rehman, Youkun Zheng, Xiaoqi Li, Xiaoli Liu, Hui Jiang, Xuemei Wang
Alzheimer's disease is still incurable neurodegenerative, and lack of detection method with high sensitivity and specificity. In this study, by taking different month old Alzheimer's mice as models, we have explored the possibility of the target bioimaging of the diseased sites through the initial injection of zinc gluconate solution into Alzheimer's model mice post tail-vein, and then combination of the further injection of ferrous chloride (FeCl2) solution into the same Alzheimer's model mice post stomach...
August 14, 2017: Langmuir: the ACS Journal of Surfaces and Colloids
https://www.readbyqxmd.com/read/28800330/pet-tau-and-amyloid-%C3%AE-burden-in-mild-alzheimer-s-disease-divergent-relationship-with-age-cognition-and-cerebrospinal-fluid-biomarkers
#10
Ivan Koychev, Roger N Gunn, Azadeh Firouzian, Jennifer Lawson, Giovanna Zamboni, Basil Ridha, Barbara J Sahakian, James B Rowe, Alan Thomas, Lynn Rochester, Dominic Ffytche, Robert Howard, Henrik Zetterberg, Clare MacKay, Simon Lovestone
BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center observational study in early AD (MMSE >20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of Aβ and tau at baseline and 6 months; PET-CT imaging with Aβ ([18F]AV45) and tau ([18F]AV1451) ligands at baseline...
August 8, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28800329/chronic-verubecestat-treatment-suppresses-amyloid-accumulation-in-advanced-aged-tg2576-a%C3%AE-ppswe-mice-without-inducing-microhemorrhage
#11
Stephanie Villarreal, Fuqiang Zhao, Lynn A Hyde, Daniel Holder, Thomas Forest, Marie Sondey, Xia Chen, Cyrille Sur, Eric M Parker, Matthew E Kennedy
Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to-moderate and prodromal Alzheimer's disease. Multiple anti-amyloid immunotherapies have been dose-limited by adverse amyloid related imaging abnormalities such as vasogenic edema (ARIA-E) and microhemorrhage (ARIA-H) observed in human trials and mice. Verubecestat was tested in a 12-week nonclinical study for the potential to exacerbate microhemorrhage (ARIA-H) profiles in 18-22-month-old post-plaque Tg2576-AβPPswe mice...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28800325/classification-of-alzheimer-s-disease-and-prediction-of-mild-cognitive-impairment-conversion-using-histogram-based-analysis-of-patient-specific-anatomical-brain-connectivity-networks
#12
Iman Beheshti, Norihide Maikusa, Morteza Daneshmand, Hiroshi Matsuda, Hasan Demirel, Gholamreza Anbarjafari
In this study, we investigated the early detection of Alzheimer's disease (AD) and mild cognitive impairment (MCI) conversion to AD through individual structural connectivity networks using structural magnetic resonance imaging (sMRI) data. In the proposed method, the cortical morphometry of individual gray matter images were used to construct structural connectivity networks. A statistical feature generation approach based on histogram-based feature generation procedure was proposed to represent a statistical-pattern of connectivity networks from a high-dimensional space into low-dimensional feature vectors...
August 8, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28799085/dimerization-leads-to-changes-in-app-amyloid-precursor-protein-trafficking-mediated-by-lrp1-and-sorla
#13
Simone Eggert, A C Gonzalez, C Thomas, S Schilling, S M Schwarz, C Tischer, V Adam, P Strecker, V Schmidt, T E Willnow, G Hermey, C U Pietrzik, E H Koo, Stefan Kins
Proteolytic cleavage of the amyloid precursor protein (APP) by α-, β- and γ-secretases is a determining factor in Alzheimer's disease (AD). Imbalances in the activity of all three enzymes can result in alterations towards pathogenic Aβ production. Proteolysis of APP is strongly linked to its subcellular localization as the secretases involved are distributed in different cellular compartments. APP has been shown to dimerize in cis-orientation, affecting Aβ production. This might be explained by different substrate properties defined by the APP oligomerization state or alternatively by altered APP monomer/dimer localization...
August 10, 2017: Cellular and Molecular Life Sciences: CMLS
https://www.readbyqxmd.com/read/28798659/enhanced-data-representation-by-kernel-metric-learning-for-dementia-diagnosis
#14
David Cárdenas-Peña, Diego Collazos-Huertas, German Castellanos-Dominguez
Alzheimer's disease (AD) is the kind of dementia that affects the most people around the world. Therefore, an early identification supporting effective treatments is required to increase the life quality of a wide number of patients. Recently, computer-aided diagnosis tools for dementia using Magnetic Resonance Imaging scans have been successfully proposed to discriminate between patients with AD, mild cognitive impairment, and healthy controls. Most of the attention has been given to the clinical data, provided by initiatives as the ADNI, supporting reliable researches on intervention, prevention, and treatments of AD...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28797599/magnetic-resonance-spectroscopy-analysis-of-neurochemical-changes-in-the-atrophic-hippocampus-of-app-ps1-transgenic-mice
#15
Shengxiang Liang, Jia Huang, Weilin Liu, Hao Jin, Long Li, Xiufeng Zhang, Binbin Nie, Ruhui Lin, Jing Tao, Shujun Zhao, Baoci Shan, Lidian Chen
Alzheimer's disease (AD) is characterized by neuropathological changes and progressive cognitive decline, which is associated with the volume loss and neurochemical alterations. However, the specific neurochemical alterations in cerebral regions that contribute to cognitive decline still remain unknown. In the present study, we measured cerebral morphological and neurochemical alterations using structural magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H-MRS) in an AD model of APP/PS1 transgenic mice...
August 8, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28796011/the-nature-and-natural-history-of-posterior-cortical-atrophy-syndrome-a-variant-of-early-onset-alzheimer-disease
#16
Peter K Panegyres, Judy Goh, Michael McCarthy, Andrew I Campbell
A prospective longitudinal evaluation of 12 patients over a 16-year interval using clinical neurological and imaging data to determine whether posterior cortical atrophy syndrome (PCA) related to early-onset Alzheimer disease (AD) and to examine its natural history. Our 12 patients had a median age of onset of 56 years (range, 48 to 63 y) and were followed for a median of 6 years (range, 3 to 9 y). Patients either presented with complex visual phenomena or developed them with time. Six patients underwent flurodeoxyglucose and Pittsburgh investigational compound B imaging which showed a mismatch between metabolic activity and amyloid deposition with reduced metabolism in parieto-occipital regions on flurodeoxyglucose positron emission tomography and diffuse neocortical uptake of amyloid without occipital predominance...
August 8, 2017: Alzheimer Disease and Associated Disorders
https://www.readbyqxmd.com/read/28795133/performance-of-18-f-flutemetamol-amyloid-imaging-against-the-neuritic-plaque-component-of-cerad-and-the-current-2012-nia-aa-recommendations-for-the-neuropathologic-diagnosis-of-alzheimer-s-disease
#17
Stephen Salloway, Jose E Gamez, Upinder Singh, Carl H Sadowsky, Teresa Villena, Marwan N Sabbagh, Thomas G Beach, Ranjan Duara, Adam S Fleisher, Kirk A Frey, Zuzana Walker, Arvinder Hunjan, Yavir M Escovar, Marc E Agronin, Joel Ross, Andrea Bozoki, Mary Akinola, Jiong Shi, Rik Vandenberghe, Milos D Ikonomovic, Paul F Sherwin, Gill Farrar, Adrian P L Smith, Christopher J Buckley, Dietmar Rudolf Thal, Michelle Zanette, Craig Curtis
INTRODUCTION: Performance of the amyloid tracer [(18)F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD "original" and "modified" and the amyloid component of the 2012 NIA-AA guidelines). METHODS: After [(18)F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28790908/multi-kernel-learning-with-dartel-improves-combined-mri-pet-classification-of-alzheimer-s-disease-in-aibl-data-group-and-individual-analyses
#18
Vahab Youssofzadeh, Bernadette McGuinness, Liam P Maguire, KongFatt Wong-Lin
Magnetic resonance imaging (MRI) and positron emission tomography (PET) are neuroimaging modalities typically used for evaluating brain changes in Alzheimer's disease (AD). Due to their complementary nature, their combination can provide more accurate AD diagnosis or prognosis. In this work, we apply a multi-modal imaging machine-learning framework to enhance AD classification and prediction of diagnosis of subject-matched gray matter MRI and Pittsburgh compound B (PiB)-PET data related to 58 AD, 108 mild cognitive impairment (MCI) and 120 healthy elderly (HE) subjects from the Australian imaging, biomarkers and lifestyle (AIBL) dataset...
2017: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/28790016/tau-imaging-in-neurodegeneration
#19
REVIEW
Gérard N Bischof, Heike Endepols, Thilo van Eimeren, Alexander Drzezga
Pathological cerebral aggregations of proteins are suggested to play a crucial role in the development of neurodegenerative disorders. For example, aggregation of the protein ß-amyloid in form of extracellular amyloid-plaques as well as intraneuronal depositions of the protein tau in form of neurofibrillary tangles represent hallmarks of Alzheimer's disease (AD). Recently, novel tracers for in vivo molecular imaging of tau-aggregates in the brain have been introduced, complementing existing tracers for imaging amyloid-plaques...
August 5, 2017: Methods: a Companion to Methods in Enzymology
https://www.readbyqxmd.com/read/28777748/fully-automatic-mri-based-hippocampus-volumetry-using-fsl-first-intra-scanner-test-retest-stability-inter-field-strength-variability-and-performance-as-enrichment-biomarker-for-clinical-trials-using-prodromal-target-populations-at-risk-for-alzheimer-s-disease
#20
Enrica Cavedo, Per Suppa, Catharina Lange, Roland Opfer, Simone Lista, Samantha Galluzzi, Adam J Schwarz, Lothar Spies, Ralph Buchert, Harald Hampel
BACKGROUND: MRI-based hippocampus volume is a core clinical biomarker for identification of Alzheimer's disease (AD). OBJECTIVE: To assess robustness of automatic hippocampus volumetry with the freely available FSL-FIRST software with respect to short-term repeat and across field strength imaging. FSL-FIRST hippocampus volume (FIRST-HV) was also evaluated as enrichment biomarker for mild cognitive impairment (MCI) trials. METHODS: Robustness of FIRST-HV was assessed in 51 healthy controls (HC), 74 MCI subjects, and 28 patients with AD dementia from ADNI1, each with two pairs of back-to-back scans, one at 1...
July 29, 2017: Journal of Alzheimer's Disease: JAD
keyword
keyword
118539
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"